首页 > 最新文献

Assay and drug development technologies最新文献

英文 中文
Nanocarrier-Mediated Dermal Drug Delivery System of Antimicrobial Agents for Targeting Skin and Soft Tissue Infections. 针对皮肤和软组织感染的纳米载体皮肤给药系统。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1089/adt.2024.060
Priya, Praveen Kumar Gaur, Shobhit Kumar

Antimicrobial resistance in disease-causing microbes is seen as a severe problem that affects the entire world, makes therapy less effective, and raises mortality rates. Dermal antimicrobial therapy becomes a desirable choice in the management of infectious disorders since the rising resistance to systemic antimicrobial treatment frequently necessitates the use of more toxic drugs. Nanoparticulate systems such as nanobactericides, which have built-in antibacterial activity, and nanocarriers, which function as drug delivery systems for conventional antimicrobials, are just two examples of the treatment methods made feasible by nanotechnology. Silver nanoparticles, zinc oxide nanoparticles, and titanium dioxide nanoparticles are examples of inorganic nanoparticles that are efficient on sensitive and multidrug-resistant bacterial strains both as nanobactericides and nanocarriers. To stop the growth of microorganisms that are resistant to standard antimicrobials, various antimicrobials for dermal application are widely used. This review covers the most prevalent microbes responsible for skin and soft tissue infections, techniques to deliver dermal antimicrobials, topical antimicrobial safety concerns, current issues, challenges, and potential future developments. A thorough and methodical search of databases, such as Google Scholar, PubMed, Science Direct, and others, using specified keyword combinations, such as "antimicrobials," "dermal," "nanocarriers," and numerous others, was used to gather relevant literature for this work.

致病微生物的抗菌药耐药性被视为影响全世界的一个严重问题,它降低了治疗效果,提高了死亡率。皮肤抗菌疗法已成为治疗感染性疾病的理想选择,因为全身性抗菌治疗的抗药性不断增加,经常需要使用毒性更强的药物。纳米颗粒系统,如具有内置抗菌活性的纳米杀菌剂和作为传统抗菌剂给药系统的纳米载体,只是纳米技术使治疗方法变得可行的两个例子。纳米银粒子、纳米氧化锌粒子和纳米二氧化钛粒子都是无机纳米粒子的例子,它们作为纳米杀菌剂和纳米载体,对敏感菌株和耐多药菌株都很有效。为了阻止对标准抗菌剂产生抗药性的微生物生长,各种皮肤用抗菌剂被广泛使用。本综述涵盖了导致皮肤和软组织感染的最常见微生物、皮肤抗菌剂的给药技术、局部抗菌剂的安全问题、当前的问题、挑战以及潜在的未来发展。本研究使用特定的关键词组合,如 "抗菌剂"、"皮肤"、"纳米载体 "等,对谷歌学术、PubMed、Science Direct 等数据库进行了全面而有条理的搜索,以收集相关文献。
{"title":"Nanocarrier-Mediated Dermal Drug Delivery System of Antimicrobial Agents for Targeting Skin and Soft Tissue Infections.","authors":"Priya, Praveen Kumar Gaur, Shobhit Kumar","doi":"10.1089/adt.2024.060","DOIUrl":"10.1089/adt.2024.060","url":null,"abstract":"<p><p>\u0000 <i>Antimicrobial resistance in disease-causing microbes is seen as a severe problem that affects the entire world, makes therapy less effective, and raises mortality rates. Dermal antimicrobial therapy becomes a desirable choice in the management of infectious disorders since the rising resistance to systemic antimicrobial treatment frequently necessitates the use of more toxic drugs. Nanoparticulate systems such as nanobactericides, which have built-in antibacterial activity, and nanocarriers, which function as drug delivery systems for conventional antimicrobials, are just two examples of the treatment methods made feasible by nanotechnology. Silver nanoparticles, zinc oxide nanoparticles, and titanium dioxide nanoparticles are examples of inorganic nanoparticles that are efficient on sensitive and multidrug-resistant bacterial strains both as nanobactericides and nanocarriers. To stop the growth of microorganisms that are resistant to standard antimicrobials, various antimicrobials for dermal application are widely used. This review covers the most prevalent microbes responsible for skin and soft tissue infections, techniques to deliver dermal antimicrobials, topical antimicrobial safety concerns, current issues, challenges, and potential future developments. A thorough and methodical search of databases, such as Google Scholar, PubMed, Science Direct, and others, using specified keyword combinations, such as \"antimicrobials,\" \"dermal,\" \"nanocarriers,\" and numerous others, was used to gather relevant literature for this work.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"2-28"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation, Characterization, and In Vitro Evaluation of Chlorogenic Acid Loaded Hydrogel Beads for the Management of Ulcerative Colitis. 绿原酸负载水凝胶珠治疗溃疡性结肠炎的制备、表征和体外评价。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1089/adt.2024.072
Ranjit K Harwansh, Hemant Bhati, Rohitas Deshmukh, Mohammad Akhlaquer Rahman

Ulcerative colitis (UC) is a chronic inflammatory colon disorder. Several modern medicines have been used for UC treatment but are associated with side effects. Hence, herbal medicine-inspired lead molecules are promising for managing UC. Chlorogenic acid (CGA), an herbal bioactive, has been reported for anti-inflammatory, anticancer, antioxidant, and immunomodulatory activity. The current study aimed to develop enteric-coated mucoadhesive beads of CGA for colon targeting. CGA-loaded beads were prepared using chitosan and carrageenan as polymers through an ionic gelation technique. Furthermore, beads were coated with Eudragit S-100. The formulations were characterized by particle size analyzer, ultraviolet (UV)-spectroscopy, Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), and in vitro drug release study. The optimized formulation (CGA-F2) showed particle size (440.6 ± 6.1 μm), zeta potential (-31.12 ± 2.16 mV), entrapment efficiency (83.56 ± 5.46), %yield (86.87 ± 4.19), and drug loading (1.14 ± 0.09). SEM indicated that the morphologies of CGA-F2 were spherical and ellipsoidal. The FTIR study confirmed the compatibility of the drug with polymers used in the formulations. CGA-F2 exhibited mucoadhesive efficiency (94.33 ± 2.1%) and swelling index (0.98 ± 0.03) at simulated colonic fluid (SCF) pH 7.4 (***p < 0.001) significantly. In an in vitro drug release study, CGA-F2 (95.07 ± 3.85%) showed a sustained drug release profile in SCF (pH 7.4) at 37 ± 0.5°C for 24 h. Optimized formulation exhibited drug release in a sustained manner for 24 h, which may be due to the effect of mucoadhesive and enteric coating polymer. Hence, CGA-loaded beads would be promising for treating the UC.

溃疡性结肠炎(UC)是一种慢性炎性结肠疾病。几种现代药物已用于UC治疗,但与副作用有关。因此,受草药启发的铅分子有望用于治疗UC。绿原酸(CGA)是一种草药生物活性物质,具有抗炎、抗癌、抗氧化和免疫调节活性。本研究旨在开发肠溶性黏附CGA微球,用于结肠靶向。以壳聚糖和卡拉胶为聚合物,采用离子凝胶技术制备了负载cga的微球。此外,用Eudragit S-100包被珠粒。采用粒度分析仪、紫外光谱(UV)、傅里叶红外光谱(FTIR)、扫描电镜(SEM)和体外释药研究对处方进行了表征。优化后的配方CGA-F2粒径为(440.6±6.1 μm), zeta电位为(-31.12±2.16 mV),包封效率为(83.56±5.46),产率为(86.87±4.19),载药量为(1.14±0.09)。扫描电镜显示CGA-F2的形貌为球形和椭球状。FTIR研究证实了该药物与配方中使用的聚合物的相容性。在模拟结肠液(SCF) pH 7.4时,CGA-F2的黏附效率为94.33±2.1%,肿胀指数为0.98±0.03 (***p < 0.001)。体外释药实验中,CGA-F2在37±0.5°C的SCF (pH 7.4)中持续释药24 h,释药率为95.07±3.85%。优化后的制剂可持续释药24 h,这可能与黏附性和肠溶包被聚合物的作用有关。因此,cga负载微球有望用于UC的治疗。
{"title":"Preparation, Characterization, and <i>In Vitro</i> Evaluation of Chlorogenic Acid Loaded Hydrogel Beads for the Management of Ulcerative Colitis.","authors":"Ranjit K Harwansh, Hemant Bhati, Rohitas Deshmukh, Mohammad Akhlaquer Rahman","doi":"10.1089/adt.2024.072","DOIUrl":"10.1089/adt.2024.072","url":null,"abstract":"<p><p>\u0000 <i>Ulcerative colitis (UC) is a chronic inflammatory colon disorder. Several modern medicines have been used for UC treatment but are associated with side effects. Hence, herbal medicine-inspired lead molecules are promising for managing UC. Chlorogenic acid (CGA), an herbal bioactive, has been reported for anti-inflammatory, anticancer, antioxidant, and immunomodulatory activity. The current study aimed to develop enteric-coated mucoadhesive beads of CGA for colon targeting. CGA-loaded beads were prepared using chitosan and carrageenan as polymers through an ionic gelation technique. Furthermore, beads were coated with Eudragit S-100. The formulations were characterized by particle size analyzer, ultraviolet (UV)-spectroscopy, Fourier transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), and <i>in vitro</i> drug release study. The optimized formulation (CGA-F2) showed particle size (440.6 ± 6.1 μm), zeta potential (-31.12 ± 2.16 mV), entrapment efficiency (83.56 ± 5.46), %yield (86.87 ± 4.19), and drug loading (1.14 ± 0.09). SEM indicated that the morphologies of CGA-F2 were spherical and ellipsoidal. The FTIR study confirmed the compatibility of the drug with polymers used in the formulations. CGA-F2 exhibited mucoadhesive efficiency (94.33 ± 2.1%) and swelling index (0.98 ± 0.03) at simulated colonic fluid (SCF) pH 7.4 (<i>***p</i> < 0.001) significantly. In an <i>in vitro</i> drug release study, CGA-F2 (95.07 ± 3.85%) showed a sustained drug release profile in SCF (pH 7.4) at 37 ± 0.5°C for 24 h. Optimized formulation exhibited drug release in a sustained manner for 24 h, which may be due to the effect of mucoadhesive and enteric coating polymer. Hence, CGA-loaded beads would be promising for treating the UC.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"29-43"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Golden Therapeutic Approach to Combat Viral Diseases Using Gold Nanomaterials. 利用金纳米材料对抗病毒性疾病的黄金治疗方法。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-11 DOI: 10.1089/adt.2024.071
Jasmine, Neelam Singh, Dheeraj Nagpal, Sanchit Puniani, Puneet Gupta

Gold nanoparticles (AuNPs), due to their unique properties and surface modification abilities, have become a promising carrier for a range of biomedical applications. AuNPs have intrinsic antiviral characteristics because of their capacity to enhance drug distribution by making antiviral medications more stable and soluble, which assures that higher quantities reach the intended site. Through surface changes, AuNPs can bind directly to viral particles or infected cells, increasing therapeutic efficiency and reducing side effects. AuNPs efficiently damage cell membranes and hinder viral reproduction within a host cell. Furthermore, because of their large surface area-to-volume ratio, which enables many functional groups to connect, improving interaction with virus particles and ceasing their multiplication. By altering dimensions and morphology or conjugating it with additional antiviral drugs, AuNPs can array their synergistic antiviral activity. Thus, the development of AuNP conjugated therapy presents a promising avenue to address the demand for novel anti-viral therapeutics against infections resistant to several drugs.

金纳米颗粒(AuNPs)由于其独特的性能和表面修饰能力,已成为一系列生物医学应用的有前途的载体。aunp具有内在的抗病毒特性,因为它们能够通过使抗病毒药物更稳定和可溶来增强药物分布,从而确保更多的药物到达预定部位。通过表面变化,AuNPs可以直接与病毒颗粒或感染细胞结合,提高治疗效率,减少副作用。AuNPs有效地破坏细胞膜并阻碍病毒在宿主细胞内的繁殖。此外,由于它们的表面积体积比大,这使得许多官能团能够连接起来,改善了与病毒颗粒的相互作用,并停止了它们的增殖。通过改变尺寸和形态或与其他抗病毒药物偶联,AuNPs可以排列其协同抗病毒活性。因此,AuNP偶联疗法的发展为解决对几种药物耐药感染的新型抗病毒治疗的需求提供了一条有希望的途径。
{"title":"Golden Therapeutic Approach to Combat Viral Diseases Using Gold Nanomaterials.","authors":"Jasmine, Neelam Singh, Dheeraj Nagpal, Sanchit Puniani, Puneet Gupta","doi":"10.1089/adt.2024.071","DOIUrl":"https://doi.org/10.1089/adt.2024.071","url":null,"abstract":"<p><p>\u0000 <i>Gold nanoparticles (AuNPs), due to their unique properties and surface modification abilities, have become a promising carrier for a range of biomedical applications. AuNPs have intrinsic antiviral characteristics because of their capacity to enhance drug distribution by making antiviral medications more stable and soluble, which assures that higher quantities reach the intended site. Through surface changes, AuNPs can bind directly to viral particles or infected cells, increasing therapeutic efficiency and reducing side effects. AuNPs efficiently damage cell membranes and hinder viral reproduction within a host cell. Furthermore, because of their large surface area-to-volume ratio, which enables many functional groups to connect, improving interaction with virus particles and ceasing their multiplication. By altering dimensions and morphology or conjugating it with additional antiviral drugs, AuNPs can array their synergistic antiviral activity. Thus, the development of AuNP conjugated therapy presents a promising avenue to address the demand for novel anti-viral therapeutics against infections resistant to several drugs.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pioneer Review on Lactoferrin-Conjugated Extracellular Nanovesicles for Targeting Cellular Melanoma: Recent Advancements and Future Prospects. 乳铁蛋白结合的细胞外纳米囊泡靶向细胞黑色素瘤的先驱综述:最新进展和未来展望。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-12-10 DOI: 10.1089/adt.2024.045
Dilpreet Singh, Sonima Prasad

Melanoma, a highly aggressive form of skin cancer, presents a formidable challenge in terms of treatment due to its propensity for metastasis and resistance to conventional therapies. The development of innovative nanocarriers for targeted drug delivery has opened new avenues in cancer therapy. Lactoferrin-conjugated extracellular nanovesicles (LF-EVs) have emerged as a promising vehicle in the targeted treatment of cellular melanoma, owing to their natural biocompatibility, enhanced bioavailability, and ability to traverse biological barriers effectively. This review synthesizes recent advancements in the use of LF-EVs as a novel drug delivery system for melanoma, emphasizing their unique capacity to enhance cellular uptake through LF's receptor-mediated endocytosis pathways. Key studies demonstrate that LF conjugation significantly increases the specificity of extracellular nanovesicles for melanoma cells, minimizes off-target effects, and promotes efficient intracellular drug release. Furthermore, we explore how LF-EVs interact with the tumor microenvironment, potentially inhibiting melanoma progression and metastasis while supporting antitumor immune responses. Future prospects in this field include optimizing LF conjugation techniques, improving the scalability of LF-EV production, and integrating multifunctional payloads to target drug resistance mechanisms. This review highlights the potential of LF-EVs to transform melanoma treatment strategies, bridging current gaps in therapeutic delivery and paving the way for personalized and less invasive melanoma therapies.

黑色素瘤是一种高度侵袭性的皮肤癌,由于其易转移和对传统疗法的抵抗,在治疗方面提出了一个巨大的挑战。纳米靶向药物载体的发展为癌症治疗开辟了新的途径。乳铁蛋白结合的细胞外纳米囊泡(lf - ev)由于其天然的生物相容性、增强的生物利用度和有效穿越生物屏障的能力,已成为靶向治疗细胞性黑色素瘤的一种有前途的载体。本文综述了LF- ev作为一种新型黑色素瘤药物递送系统的最新进展,强调了它们通过LF受体介导的内吞作用途径增强细胞摄取的独特能力。关键研究表明,LF偶联可显著提高黑色素瘤细胞外纳米囊泡的特异性,最大限度地减少脱靶效应,并促进细胞内有效的药物释放。此外,我们探讨了lf - ev如何与肿瘤微环境相互作用,潜在地抑制黑色素瘤的进展和转移,同时支持抗肿瘤免疫反应。该领域的未来发展前景包括优化LF偶联技术,提高LF- ev生产的可扩展性,以及将多功能有效载荷集成到靶向耐药机制中。本综述强调了lf - ev改变黑色素瘤治疗策略的潜力,弥补了目前治疗递送方面的差距,并为个性化和低侵入性黑色素瘤治疗铺平了道路。
{"title":"A Pioneer Review on Lactoferrin-Conjugated Extracellular Nanovesicles for Targeting Cellular Melanoma: Recent Advancements and Future Prospects.","authors":"Dilpreet Singh, Sonima Prasad","doi":"10.1089/adt.2024.045","DOIUrl":"https://doi.org/10.1089/adt.2024.045","url":null,"abstract":"<p><p>\u0000 <i>Melanoma, a highly aggressive form of skin cancer, presents a formidable challenge in terms of treatment due to its propensity for metastasis and resistance to conventional therapies. The development of innovative nanocarriers for targeted drug delivery has opened new avenues in cancer therapy. Lactoferrin-conjugated extracellular nanovesicles (LF-EVs) have emerged as a promising vehicle in the targeted treatment of cellular melanoma, owing to their natural biocompatibility, enhanced bioavailability, and ability to traverse biological barriers effectively. This review synthesizes recent advancements in the use of LF-EVs as a novel drug delivery system for melanoma, emphasizing their unique capacity to enhance cellular uptake through LF's receptor-mediated endocytosis pathways. Key studies demonstrate that LF conjugation significantly increases the specificity of extracellular nanovesicles for melanoma cells, minimizes off-target effects, and promotes efficient intracellular drug release. Furthermore, we explore how LF-EVs interact with the tumor microenvironment, potentially inhibiting melanoma progression and metastasis while supporting antitumor immune responses. Future prospects in this field include optimizing LF conjugation techniques, improving the scalability of LF-EV production, and integrating multifunctional payloads to target drug resistance mechanisms. This review highlights the potential of LF-EVs to transform melanoma treatment strategies, bridging current gaps in therapeutic delivery and paving the way for personalized and less invasive melanoma therapies.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration. 利甘定能改善高脂饮食和链脲佐菌素诱发的 2 型糖尿病并防止胰岛退化
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-11-01 Epub Date: 2024-11-06 DOI: 10.1089/adt.2024.029
Deepa Sugumar, Ritaban Ghosh, Emdormi Rymbai, Jaikanth Chandrasekaran, Praveen Thaggikuppe Krishnamurthy, Ranjith S P, Shreya Sahu, Divakar Selvaraj

Androgen therapy has been shown to alleviate type 2 diabetes mellitus (T2DM) but is also associated with severe side effects such as prostate cancer. The present study aims to identify the best hit selective androgen receptor (AR) modulator by in silico studies and then investigates its antidiabetic effects in high-fat diet- and streptozotocin (STZ)-induced T2DM male rat model. Molecular docking and molecular dynamics (MD) studies were carried out using Maestro 13.1 and Desmond (2023-2024). Cytotoxicity and insulin secretion were measured in MIN6 cell lines. T2DM was induced using high-fat diet (HFD) for 4 weeks, followed by single STZ (40 mg/kg, intraperitoneally). OneTouch Ultra glucometer was used to measure fasting blood glucose. Gene expression was determined using reverse transcription polymerase chain reaction. Histopathology was carried out using hematoxylin and eosin stain. Through molecular docking, we identify ligandrol as a potential hit. Ligandrol showed a good binding affinity (-10.74 kcal/mol). MD showed that ligandrol is stable during the 100 ns simulation. Ligandrol increases insulin secretion in a dose-dependent manner in vitro in 2 h. Ligandrol (0.3 and 1 mg/kg, orally) significantly decreased the body weight and fasting blood glucose levels compared with the HFD and STZ group. Gene expression showed that ligandrol significantly increased the AR-targeted gene, neurogenic differentiation 1, compared with the HFD and STZ group. Histopathological staining studies showed that ligandrol prevents pancreatic islet degeneration compared with the HFD and STZ group. Our findings suggest that ligandrol's protective effect on pancreatic islets leading to its antidiabetic effect occurs through the activation of AR.

雄激素疗法已被证明可以缓解 2 型糖尿病(T2DM),但也与前列腺癌等严重副作用相关。本研究旨在通过硅学研究确定最佳的选择性雄激素受体(AR)调节剂,然后研究其在高脂饮食和链脲佐菌素(STZ)诱导的 T2DM 雄性大鼠模型中的抗糖尿病作用。使用 Maestro 13.1 和 Desmond (2023-2024) 进行了分子对接和分子动力学(MD)研究。在 MIN6 细胞系中测量了细胞毒性和胰岛素分泌。使用高脂饮食(HFD)诱导 T2DM 4 周,然后腹腔注射单次 STZ(40 毫克/千克)。使用OneTouch Ultra血糖仪测量空腹血糖。使用反转录聚合酶链反应测定基因表达。组织病理学采用苏木精和伊红染色法。通过分子对接,我们确定配糖体为潜在的靶点。Ligandrol 显示出良好的结合亲和力(-10.74 kcal/mol)。MD 显示,配糖体在 100 ns 模拟期间是稳定的。与 HFD 和 STZ 组相比,Ligandrol(0.3 和 1 mg/kg,口服)能显著降低体重和空腹血糖水平。基因表达显示,与高纤维食物组和 STZ 组相比,利甘醇能显著增加 AR 靶向基因神经源性分化 1。组织病理学染色研究表明,与高脂饮食组和 STZ 组相比,利甘醇可防止胰岛变性。我们的研究结果表明,利甘醇对胰岛的保护作用是通过激活 AR 来实现的,从而产生抗糖尿病作用。
{"title":"Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration.","authors":"Deepa Sugumar, Ritaban Ghosh, Emdormi Rymbai, Jaikanth Chandrasekaran, Praveen Thaggikuppe Krishnamurthy, Ranjith S P, Shreya Sahu, Divakar Selvaraj","doi":"10.1089/adt.2024.029","DOIUrl":"10.1089/adt.2024.029","url":null,"abstract":"<p><p>Androgen therapy has been shown to alleviate type 2 diabetes mellitus (T2DM) but is also associated with severe side effects such as prostate cancer. The present study aims to identify the best hit selective androgen <i>receptor</i> (AR) modulator by <i>in silico</i> studies and then investigates its antidiabetic effects in high-fat diet- and streptozotocin (STZ)-induced T2DM male rat model. Molecular docking and molecular dynamics (MD) studies were carried out using Maestro 13.1 and Desmond (2023-2024). Cytotoxicity and insulin secretion were measured in MIN6 cell lines. T2DM was induced using high-fat diet (HFD) for 4 weeks, followed by single STZ (40 mg/kg, intraperitoneally). OneTouch Ultra glucometer was used to measure fasting blood glucose. Gene expression was determined using reverse transcription polymerase chain reaction. Histopathology was carried out using hematoxylin and eosin stain. Through molecular docking, we identify ligandrol as a potential hit. Ligandrol showed a good binding affinity (-10.74 kcal/mol). MD showed that ligandrol is stable during the 100 ns simulation. Ligandrol increases insulin secretion in a dose-dependent manner <i>in vitro</i> in 2 h. Ligandrol (0.3 and 1 mg/kg, orally) significantly decreased the body weight and fasting blood glucose levels compared with the HFD and STZ group. Gene expression showed that ligandrol significantly increased the AR-targeted gene, <i>neurogenic differentiation 1</i>, compared with the HFD and STZ group. Histopathological staining studies showed that ligandrol prevents pancreatic islet degeneration compared with the HFD and STZ group. Our findings suggest that ligandrol's protective effect on pancreatic islets leading to its antidiabetic effect occurs through the activation of AR.</p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"397-408"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) Method Development and Validation Using Analytical Quality-by-Design Approach for Determination of Isoliquiritigenin in Bulk and Biological Sample. 采用 "分析质量源于设计 "方法开发和验证反相高效液相色谱 (RP-HPLC) 方法,用于测定大宗样品和生物样品中的异桔梗苷元。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-11-01 Epub Date: 2024-11-25 DOI: 10.1089/adt.2024.050
Mohamed Nihal P, Debasish Mohapatra, Alam Mohd Adil Alam Manir, Vancha Harish, Sachin Kumar Singh, Sakshi Upendra Lad, Srinivas Sutrapu, Sumant Saini, Sharfuddin Mohd

The primary objective of the present investigation is to develop and validate a simple, robust, and cost-effective isocratic reverse phase-high-performance liquid chromatography (RP-HPLC) method for determining isoliquiritigenin (ISL) in both bulk and biological samples using an analytical quality-by-design (AQbD) approach. The central composite design was employed for method optimization using Design Expert® software, by taking mobile phase ratio and flow rate as independent variables and peak area, retention time, tailing factor, and theoretical plates as dependent variables. The design suggested the use of a mobile phase consisting of acetonitrile:0.2% ortho-phosphoric acid (75:25, v/v) and a flow rate of 0.9 mL/min as optimal chromatographic conditions. The detection of ISL was performed at 364 nm. The optimized method was validated in accordance with International Conference on Harmonization (ICH) Q2(R1) guidelines. The method showed excellent linearity, limit of detection, limit of quantification, accuracy, precision, robustness, and system suitability. All validation parameters fell within the acceptable limits set by ICH. Additionally, the applicability of the method in biological samples were analyzed. In conclusion, the results suggest that the developed and validated AQbD-based RP-HPLC method was well-suited for the estimation of ISL in bulk and biological sample.

本研究的主要目的是采用质量源于设计的分析方法(AQbD),开发并验证一种简单、稳健、经济高效的等度反相高效液相色谱(RP-HPLC)方法,用于测定散装样品和生物样品中的异桔梗皂苷(ISL)。以流动相比例和流速为自变量,以峰面积、保留时间、尾随因子和理论平板为因变量,使用 Design Expert® 软件对方法进行了中心复合设计优化。设计结果表明,乙腈:0.2% 原磷酸(75:25, v/v)组成的流动相和 0.9 mL/min 的流速是最佳的色谱条件。ISL 的检测波长为 364 nm。根据国际协调会议(ICH)Q2(R1)指南对优化后的方法进行了验证。该方法在线性、检出限、定量限、准确度、精密度、稳健性和系统适用性方面均表现优异。所有验证参数都在 ICH 规定的可接受范围内。此外,还分析了该方法在生物样品中的适用性。总之,研究结果表明,所开发和验证的基于 AQbD 的 RP-HPLC 方法非常适合用于大宗样品和生物样品中 ISL 的估计。
{"title":"Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) Method Development and Validation Using Analytical Quality-by-Design Approach for Determination of Isoliquiritigenin in Bulk and Biological Sample.","authors":"Mohamed Nihal P, Debasish Mohapatra, Alam Mohd Adil Alam Manir, Vancha Harish, Sachin Kumar Singh, Sakshi Upendra Lad, Srinivas Sutrapu, Sumant Saini, Sharfuddin Mohd","doi":"10.1089/adt.2024.050","DOIUrl":"10.1089/adt.2024.050","url":null,"abstract":"<p><p>The primary objective of the present investigation is to develop and validate a simple, robust, and cost-effective isocratic reverse phase-high-performance liquid chromatography (RP-HPLC) method for determining isoliquiritigenin (ISL) in both bulk and biological samples using an analytical quality-by-design (AQbD) approach. The central composite design was employed for method optimization using Design Expert® software, by taking mobile phase ratio and flow rate as independent variables and peak area, retention time, tailing factor, and theoretical plates as dependent variables. The design suggested the use of a mobile phase consisting of acetonitrile:0.2% ortho-phosphoric acid (75:25, v/v) and a flow rate of 0.9 mL/min as optimal chromatographic conditions. The detection of ISL was performed at 364 nm. The optimized method was validated in accordance with International Conference on Harmonization (ICH) Q2(R1) guidelines. The method showed excellent linearity, limit of detection, limit of quantification, accuracy, precision, robustness, and system suitability. All validation parameters fell within the acceptable limits set by ICH. Additionally, the applicability of the method in biological samples were analyzed. In conclusion, the results suggest that the developed and validated AQbD-based RP-HPLC method was well-suited for the estimation of ISL in bulk and biological sample.</p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"409-424"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Time of Transition: Looking Back with Gratitude, Forward with Optimism. 过渡时期:感恩回首,乐观前行。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-11-01 Epub Date: 2024-11-12 DOI: 10.1089/adt.2024.123
Bruce J Melancon
{"title":"A Time of Transition: Looking Back with Gratitude, Forward with Optimism.","authors":"Bruce J Melancon","doi":"10.1089/adt.2024.123","DOIUrl":"10.1089/adt.2024.123","url":null,"abstract":"","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"395-396"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Pharmaceutical Cocrystal Consisting of Chlorzoxazone and Nicotinamide: A New Promising Carrier for Solubility Augmentation. 由氯唑沙宗和烟酰胺组成的新型药用共晶体:一种用于增加溶解度的新型载体。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-11-01 Epub Date: 2024-11-08 DOI: 10.1089/adt.2024.051
Arzoo Sekhani, Rahul Jha, Pranav J Shah

Chlorzoxazone (CHZ) is a centrally acting muscle relaxant used to treat muscle spasms. It is employed as a first-line medication for treating muscle spasms, offering both musculoskeletal relaxation and mild sedative effects. According to the biopharmaceutics classification system, it belongs to class II drug having poor solubility and high permeability. In order to improve the flow property, water solubility, and dissolution of CHZ, CHZ-nicotinamide (NA) cocrystal was prepared by liquid-assisted grinding cocrystallization (LAG CC) method using methanol as the choice of solvent. CHZ-NA cocrystal was characterized by differential scanning calorimeter (DSC), powder X-ray diffraction (PXRD), Fourier transform infrared spectrometry, and scanning electron microscopy (SEM). DSC scan showed a sharp endothermic peak shift, which is caused by the formation of a new crystal form with altered physical properties, which was further confirmed by PXRD. Also, a change in the surface morphology of LAG CC compared to CHZ was observed in SEM. The resultant CHZ-NA cocrystal displayed improved powder flow properties compared to the native form of CHZ. LAG CC demonstrated a 3.1- and 2.6-fold increase in saturated solubility and intrinsic dissolution rate, respectively, compared to CHZ alone. Furthermore, the in vitro dissolution study showed that the cumulative dissolution of CHZ in 2 h was about 53%. Whereas, dissolution of LAG CC reached 99% in 2 h, showing obvious dissolution improvement. Thus, CHZ-NA cocrystal could significantly improve the flow properties, solubility and dissolution of CHZ.

氯唑沙宗(CHZ)是一种中枢作用的肌肉松弛剂,用于治疗肌肉痉挛。它是治疗肌肉痉挛的一线药物,具有肌肉骨骼放松和轻度镇静作用。根据生物制药分类系统,它属于溶解性差、渗透性高的第二类药物。为了改善 CHZ 的流动性、水溶性和溶解性,研究人员选择甲醇为溶剂,采用液体辅助研磨结晶(LAG CC)法制备了 CHZ-烟酰胺(NA)共晶体。差示扫描量热仪(DSC)、粉末 X 射线衍射(PXRD)、傅立叶变换红外光谱和扫描电子显微镜(SEM)对 CHZ-NA 共晶体进行了表征。DSC 扫描显示出急剧的内热峰移动,这是由于形成了一种物理性质发生变化的新晶体,PXRD 进一步证实了这一点。此外,扫描电镜还观察到 LAG CC 的表面形态与 CHZ 相比发生了变化。与原生形态的 CHZ 相比,生成的 CHZ-NA 共晶体显示出更好的粉末流动特性。与单独的 CHZ 相比,LAG CC 的饱和溶解度和内在溶解速率分别提高了 3.1 倍和 2.6 倍。此外,体外溶解研究表明,CHZ 在 2 小时内的累积溶解度约为 53%。而 LAG CC 在 2 小时内的溶出率达到 99%,显示出明显的溶出改善。因此,CHZ-NA 共晶体可显著改善 CHZ 的流动性、溶解性和溶解度。
{"title":"Novel Pharmaceutical Cocrystal Consisting of Chlorzoxazone and Nicotinamide: A New Promising Carrier for Solubility Augmentation.","authors":"Arzoo Sekhani, Rahul Jha, Pranav J Shah","doi":"10.1089/adt.2024.051","DOIUrl":"10.1089/adt.2024.051","url":null,"abstract":"<p><p>\u0000 <i>Chlorzoxazone (CHZ) is a centrally acting muscle relaxant used to treat muscle spasms. It is employed as a first-line medication for treating muscle spasms, offering both musculoskeletal relaxation and mild sedative effects. According to the biopharmaceutics classification system, it belongs to class II drug having poor solubility and high permeability. In order to improve the flow property, water solubility, and dissolution of CHZ, CHZ-nicotinamide (NA) cocrystal was prepared by liquid-assisted grinding cocrystallization (LAG CC) method using methanol as the choice of solvent. CHZ-NA cocrystal was characterized by differential scanning calorimeter (DSC), powder X-ray diffraction (PXRD), Fourier transform infrared spectrometry, and scanning electron microscopy (SEM). DSC scan showed a sharp endothermic peak shift, which is caused by the formation of a new crystal form with altered physical properties, which was further confirmed by PXRD. Also, a change in the surface morphology of LAG CC compared to CHZ was observed in SEM. The resultant CHZ-NA cocrystal displayed improved powder flow properties compared to the native form of CHZ. LAG CC demonstrated a 3.1- and 2.6-fold increase in saturated solubility and intrinsic dissolution rate, respectively, compared to CHZ alone. Furthermore, the <i>in vitro</i> dissolution study showed that the cumulative dissolution of CHZ in 2 h was about 53%. Whereas, dissolution of LAG CC reached 99% in 2 h, showing obvious dissolution improvement. Thus, CHZ-NA cocrystal could significantly improve the flow properties, solubility and dissolution of CHZ.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"425-434"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking Antioxidant-Anticancer Synergy: An Exploration of Therapeutic Bioactives from Methanolic Extracts of Rubus ellipticus and Boerhavia diffusa Using HeLa Cell Line. 揭示抗氧化剂与抗癌剂的协同作用:利用 HeLa 细胞系探索椭圆茜草和白苧麻甲醇提取物中的治疗生物活性物质
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI: 10.1089/adt.2024.040
Vipresh Bhardwaj, G T Kulkarni, Kalpana Nagpal

This study aimed to assess the synergistic antioxidant and anticancer effects of methanolic extracts derived from Rubus ellipticus and Boerhavia diffusa fruits against the HeLa cell line. The methanolic extracts were prepared from the fruits of R. ellipticus and B. diffusa, and their antioxidant potential was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity assay and the ferric reducing antioxidant power (FRAP) assay. The anticancer effects of benzoic acid and rutin extracted from the aforementioned fruits were also investigated against the HeLa cell line using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay to measure the cell metabolic activity. Using Synergy Finder plus software, the bioactive compounds were tested to explore any synergistic effects. R. ellipticus exhibited higher antioxidant potential as revealed by higher DPPH scavenging activity and FRAP value compared with B. diffusa. The benzoic acid extracted from R. ellipticus demonstrated potent anticancer activity against the HeLa cell line, with an IC50 of 1.07 µg/mL. Similarly, rutin extracted from B. diffusa displayed moderate anticancer activity with an IC50 of 1.4 µg/mL while exhibiting minimal impact on normal cell lines. The combination studies of the extracted bioactive compounds revealed a synergistic effect. These findings suggest the therapeutic potential of R. ellipticus and B. diffusa in combating the oxidative stress and cancer. Their bioactive compounds like benzoic acid and rutin were observed to act synergistically. Further investigations are warranted to elucidate the underlying mechanisms and evaluate their applicability in clinical settings.

本研究旨在评估从椭圆茜草(Rubus ellipticus)和白苧(Boerhavia diffusa)果实中提取的甲醇提取物对 HeLa 细胞系的协同抗氧化和抗癌作用。从椭圆茜和白苧的果实中提取甲醇提取物,并使用 2,2-二苯基-1-苦基肼(DPPH)清除活性测定法和铁还原抗氧化力(FRAP)测定法评估其抗氧化潜力。此外,还使用 3-(4,5-二甲基噻唑基-2)-2,5-二苯基溴化四唑测定法来测量细胞代谢活性,从而研究了从上述水果中提取的苯甲酸和芦丁对 HeLa 细胞系的抗癌作用。利用 Synergy Finder plus 软件,对生物活性化合物进行了测试,以探索是否存在协同效应。与 B. diffusa 相比,R. ellipticus 具有更高的 DPPH 清除活性和 FRAP 值,表现出更高的抗氧化潜力。从 R. ellipticus 中提取的苯甲酸对 HeLa 细胞系具有很强的抗癌活性,其 IC50 值为 1.07 µg/mL。同样,从白花蛇舌草中提取的芦丁也显示出中等程度的抗癌活性,其 IC50 值为 1.4 µg/mL,而对正常细胞系的影响则微乎其微。对提取的生物活性化合物进行的组合研究显示了协同效应。这些研究结果表明,R. ellipticus 和 B. diffusa 在对抗氧化应激和癌症方面具有治疗潜力。据观察,苯甲酸和芦丁等生物活性化合物具有协同作用。还需要进一步研究以阐明其潜在机制,并评估它们在临床环境中的适用性。
{"title":"Unlocking Antioxidant-Anticancer Synergy: An Exploration of Therapeutic Bioactives from Methanolic Extracts of <i>Rubus ellipticus</i> and <i>Boerhavia diffusa</i> Using HeLa Cell Line.","authors":"Vipresh Bhardwaj, G T Kulkarni, Kalpana Nagpal","doi":"10.1089/adt.2024.040","DOIUrl":"10.1089/adt.2024.040","url":null,"abstract":"<p><p>\u0000 <i>This study aimed to assess the synergistic antioxidant and anticancer effects of methanolic extracts derived from <i>Rubus ellipticus</i> and <i>Boerhavia diffusa</i> fruits against the HeLa cell line. The methanolic extracts were prepared from the fruits of <i>R. ellipticus</i> and <i>B. diffusa</i>, and their antioxidant potential was evaluated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity assay and the ferric reducing antioxidant power (FRAP) assay. The anticancer effects of benzoic acid and rutin extracted from the aforementioned fruits were also investigated against the HeLa cell line using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay to measure the cell metabolic activity. Using Synergy Finder plus software, the bioactive compounds were tested to explore any synergistic effects. <i>R. ellipticus</i> exhibited higher antioxidant potential as revealed by higher DPPH scavenging activity and FRAP value compared with <i>B. diffusa</i>. The benzoic acid extracted from <i>R. ellipticus</i> demonstrated potent anticancer activity against the HeLa cell line, with an IC<sub>50</sub> of 1.07 µg/mL. Similarly, rutin extracted from <i>B. diffusa</i> displayed moderate anticancer activity with an IC<sub>50</sub> of 1.4 µg/mL while exhibiting minimal impact on normal cell lines. The combination studies of the extracted bioactive compounds revealed a synergistic effect. These findings suggest the therapeutic potential of <i>R. ellipticus</i> and <i>B. diffusa</i> in combating the oxidative stress and cancer. Their bioactive compounds like benzoic acid and rutin were observed to act synergistically. Further investigations are warranted to elucidate the underlying mechanisms and evaluate their applicability in clinical settings.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"361-372"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141858935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Repurposing Patent Applications: April-June 2024. 药物再利用专利申请:2024 年 4 月至 6 月。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1089/adt.2024.081
Hermann A M Mucke
{"title":"Drug Repurposing Patent Applications: April-June 2024.","authors":"Hermann A M Mucke","doi":"10.1089/adt.2024.081","DOIUrl":"10.1089/adt.2024.081","url":null,"abstract":"","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"387-394"},"PeriodicalIF":1.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Assay and drug development technologies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1